ESTA icon

Establishment Labs

40.01 USD
+1.07
2.75%
At close Dec 20, 4:00 PM EST
1 day
2.75%
5 days
-13.00%
1 month
-4.31%
3 months
-5.75%
6 months
-6.37%
Year to date
50.47%
1 year
73.28%
5 years
54.12%
10 years
61.66%
 

About: Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing silicone-filled breast and body shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.

Employees: 933

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

17% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 7 (+1) [Q3]

15% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 34

6% more funds holding

Funds holding: 122 [Q2] → 129 (+7) [Q3]

11.49% less ownership

Funds ownership: 97.93% [Q2] → 86.44% (-11.49%) [Q3]

15% less capital invested

Capital invested by funds: $1.22B [Q2] → $1.04B (-$179M) [Q3]

23% less call options, than puts

Call options by funds: $13M | Put options by funds: $16.9M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$50
25%
upside
Avg. target
$58
44%
upside
High target
$65
62%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
BTIG
Marie Thibault
85% 1-year accuracy
11 / 13 met price target
62%upside
$65
Buy
Maintained
14 Oct 2024
Citigroup
Joanne Wuensch
55% 1-year accuracy
26 / 47 met price target
25%upside
$50
Neutral
Maintained
1 Oct 2024

Financial journalist opinion

Neutral
Business Wire
1 month ago
Establishment Labs Announces Participation in Upcoming Investment Conferences
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in three upcoming investment conferences. Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2024 UBS Global Healthcare Conference being held November 11-14, 2024. Mr. Chac.
Establishment Labs Announces Participation in Upcoming Investment Conferences
Neutral
Seeking Alpha
1 month ago
Establishment Labs Holdings Inc. (ESTA) Q3 2024 Earnings Call Transcript
Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Rajbir Denhoy - Chief Financial Officer Juan Jose - CEO and Founder Conference Call Participants Allen Gong - JPMorgan Matt Taylor - Jefferies Sam Eiber - BTIG Anthony Pettinari - Citi Josh Jennings - TD Cowen Anthony Petrone - Mizuho Group Operator Good afternoon. Welcome to Establishment Labs Third Quarter 2024 Earnings Conference Call.
Establishment Labs Holdings Inc. (ESTA) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Misses Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $1.12 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Misses Revenue Estimates
Neutral
Business Wire
1 month ago
Establishment Labs Announces $50 Million Registered Direct Offering
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with select purchasers for the purchase of 765,696 common shares and pre-funded warrants to purchase up to 328,161 common shares in a registered direct offering for a.
Establishment Labs Announces $50 Million Registered Direct Offering
Neutral
Business Wire
1 month ago
Establishment Labs Reports Third Quarter 2024 Financial Results
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2024. Third Quarter Highlights and Outlook Third quarter worldwide revenue of $40.2 million. 2024 revenue guidance updated to $165 million to $168 million from previous guidance of $174 million to $184 mill.
Establishment Labs Reports Third Quarter 2024 Financial Results
Neutral
Business Wire
1 month ago
Establishment Labs Announces Three-Year Mia Femtech Clinical Results at 9th World Symposium on Ergonomic Implants
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of three-year clinical results with Mia Femtech™ at the 9th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Barcelona, Spain. The Mia Femtech Clinical Study is an IRB-approved prospective study that enrolled 100 subjects betwee.
Establishment Labs Announces Three-Year Mia Femtech Clinical Results at 9th World Symposium on Ergonomic Implants
Neutral
Business Wire
1 month ago
Establishment Labs to Announce Third Quarter 2024 Financial Results on November 7
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S.
Establishment Labs to Announce Third Quarter 2024 Financial Results on November 7
Neutral
Business Wire
2 months ago
Establishment Labs Publishes 2024 Post Market Surveillance Report
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that it has published its 2024 Post Market Surveillance (PMS) Report. “It is fitting that as we publish our 2024 PMS report, we begin broadly shipping across the United States,” said Juan José Chacón-Quirós, Establishment Labs CEO and Founder. “Dozens of plastic surgeons.
Establishment Labs Publishes 2024 Post Market Surveillance Report
Positive
GuruFocus
2 months ago
Establishment Labs Holdings Inc (ESTA) Stock Price Up 9.25% on Oct 2
Shares of Establishment Labs Holdings Inc (ESTA, Financial) surged 9.25% in mid-day trading on Oct 2. The stock reached an intraday high of $44.42, before settling at $44.31, up from its previous close of $40.56.
Establishment Labs Holdings Inc (ESTA) Stock Price Up 9.25% on Oct 2
Neutral
Business Wire
2 months ago
First U.S. Women Successfully Receive Breast Augmentation with New FDA Approved Motiva Implants
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that the first patients in the United States have successfully undergone breast augmentation with Motiva® Implants. “With the FDA approval last week, we are experiencing high demand for Motiva Implants — both from surgeons and patients,” said Juan José Chacón-Quirós.
First U.S. Women Successfully Receive Breast Augmentation with New FDA Approved Motiva Implants
Charts implemented using Lightweight Charts™